CUTTING-EDGE TRANSCRIPTOMICS TO IDENTIFY LEUKEMIA-INTRINSIC AND -EXTRINSIC CORRELATES OF IMMUNE ESCAPE AND POST-TRANSPLANTATION RELAPSE

EHA Library, Pier Edoardo Rovatti, 386265

EFFECTIVE IMMUNOTHERAPY OF PEDIATRIC T(8;21) ACUTE MYELOID LEUKEMIA BY REPURPOSING CD3XCD19 TARGETING BISPECIFIC ANTIBODIES

EHA Library, Noa Wijnen, 386266

CLINICAL AND MOLECULAR CHARACTERISTICS OF AML PATIENTS WITH AN EXCEPTIONAL RESPONSE TO IVOSIDENIB

EHA Library, Eytan Stein, 386270

A POOLED FOCUSED IN VIVO CRISPR-CAS9 SCREENING IN IMMUNOCOMPETENT MICE ALLOWS IDENTIFICATION OF IMMUNE CHECKPOINTS RELEVANT FOR LEUKEMIC STEM CELLS

EHA Library, Chantal Bachmann, 386272

PROGNOSTIC SIGNIFICANCE OF MEASURABLE RESIDUAL DISEASE DETECTION BY FLOW CYTOMETRY IN AUTOLOGOUS STEM CELL APHERESIS PRODUCTS OF PATIENTS WITH AML

EHA Library, Jesse Tettero, 386277

GENE FUSIONS AND OTHER GENOMIC EVENTS UNDERLIE VENETOCLAX AND HYPOMETHYLATING AGENT RESISTANCE AND PROVIDE NEW TARGETS IN ACUTE MYELOID LEUKEMIA.

EHA Library, Anna Ferrari, 386280

CD4+ T CELLS REDUCE THE POPULATION OF LEUKEMIC STEM CELLS IN ACUTE MYELOID LEUKEMIA

EHA Library, Noah Schnüriger, 386281

RUNX1 DIRECTLY BINDS AND REGULATES THE TCF4 PROMOTER

EHA Library, Mylene Gerritsen, 386284

LEUKEMOGENESIS BY AML-SPECIFIC DRIVER MUTATIONS WITHIN DNMT3A, IDH2 AND NPM1

EHA Library, Ecmel Mehmetbeyoglu, 386285

COMPLEX CARYOTYPE IS AN INDEPENDENT RISK FACTOR IN TP53-MUTATED AML

EHA Library, Christian Rausch, 386286

HIPSC DISEASE MODELING TO STUDY LEUKEMIA DEVELOPMENT IN HAX1 VS ELANE ASSOCIATED CONGENITAL NEUTROPENIA

EHA Library, Benjamin Dannenmann, 386287

DATABASE GUIDED STRATEGY FOR THE CHARACTERIZATION OF LEUKEMIC STEM CELL IN ACUTE MYELOBLASTIC LEUKEMIA. IMPLICATIONS IN THE DIAGNOSIS AND PROGNOSIS OF THE DISEASE.

EHA Library, Paula Piñero, 386292

PULSE DOSING OF POTENT AND SELECTIVE HETEROBIFUNCTIONAL MDM2 DEGRADER KT-253 DRIVES TUMOR REGRESSION AND DEMONSTRATES DIFFERENTIATED PHARMACOLOGY COMPARED TO P53/MDM2 SMALL MOLECULE INHIBITORS.

EHA Library, Nancy Dumont, 386293

THE INTRINSICALLY DISORDERED TRANSCRIPTIONAL REGULATOR MN1 DEPENDS ON THE CHAPERONE DNAJB6B FOR ITS FULL TRANSFORMING POTENTIAL

EHA Library, Diego A Pereira-Martins, 386295

DETECTION AND CHARACTERIZATION OF RESIDUAL LEUKEMIC CELLS IN CHILDHOOD ACUTE MYELOID LEUKEMIA USING TARGETED DEEP SEQUENCING AND SINGLE CELL MULTI-OMICS

EHA Library, Borhan R Saeed, 386297

SINGLE-CELL METABOLIC MULTIOMICS TO IDENTIFY VULNERABILITIES IN ACUTE MYELOID LEUKEMIA STEM CELLS

EHA Library, Magdalena Antes, 386299

SINGLE-CELL PROFILING REVEALS HETEROGENEITY OF EXPANDED PLASMACYTOID DENDRITIC CELLS IN ACUTE MYELOID LEUKEMIA

EHA Library, Juan Peng, 386301

CRISPR/CAS9 GENE EDITING CLARIFIES THE ROLE OF CD33 SNP RS12459419 IN GEMTUZUMAB OZOGAMICIN-MEDIATED CYTOTOXICITY

EHA Library, Shuki Oya, 386302

FUNCTIONAL (PHOSPHO-)PROTEOMICS OF DRUG RESPONSE IN ACUTE MYELOID LEUKEMIA

EHA Library, Florian Meier-Rosar, 386303

FAILURE OF BONE MARROW ERYTHROPOIESIS IN ACUTE MYELOID LEUKEMIA IS DRIVEN BY LOSS OF ERYTHROBLASTIC ISLANDS

EHA Library, Delfim Duarte, 386310

ACCUFUSION: A HIGHLY SCALABLE SOFTWARE TOOL FOR DETECTING GENE FUSIONS BY RNA-SEQ IN LEUKEMIA

EHA Library, Xiaoping Su, 386311

AZACITIDINE, VENETOCLAX AND GILTERITINIB FOR PATIENTS WITH NEWLY DIAGNOSED FLT3-MUTATED ACUTE MYELOID LEUKEMIA: A SUBGROUP ANALYSIS FROM A PHASE II STUDY

EHA Library, Nicholas Short, 386314

SAFETY AND EFFICACY OF VENETOCLAX PLUS “7+3” CHEMOTHERAPY IN NEWLY DIAGNOSED AML

EHA Library, Ioannis Mantzaris, 386317

UPDATED SURVIVAL, BLOOD COUNT RECOVERY AND SAFETY RESULTS FROM THE AGILE STUDY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH IVOSIDENIB + AZACITIDINE COMPARED TO PLACEBO + AZACITIDINE

EHA Library, Hartmut Döhner, 386319

SAFETY AND EFFICACY OF LP-108 AS MONOTHERAPY AND COMBINED WITH AZACITIDINE IN PATIENTS WITH RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA, OR ACUTE MYELOID LEUKEMIA

EHA Library, Kristin Koenig, 386321

ORAL-ATO/ATRA/ASCORBIC ACID (AAA)-BASED INDUCTION OR MAINTENANCE OF FIRST COMPLETE REMISSION IMPROVED OUTCOMES IN NEWLY DIAGNOSED APL: A MULTICENTRE ANALYSIS OF THE APL ASIAN CONSORTIUM (APLAC)

EHA Library, Harinder Gill, 386322

CLINICAL OUTCOMES OF NPM1-MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS WITH MEASURABLE RESIDUAL DISEASE (MRD) RELAPSE AFTER ACHIEVEMENT OF A FIRST MRD-NEGATIVE REMISSION

EHA Library, Madlen Jentzsch, 386326

ISATUXIMAB PLUS CHEMOTHERAPY FOR PEDIATRIC RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA OR ACUTE MYELOID LEUKEMIA (ISAKIDS): INTERIM EFFICACY ANALYSIS

EHA Library, André Baruchel, 386330

A RANDOMISED TRIAL OF MOLECULAR MONITORING VERSUS STANDARD CLINICAL CARE IN YOUNGER ADULTS WITH ACUTE MYELOID LEUKAEMIA: RESULTS FROM THE UK NCRI AML17 AND AML19 STUDIES

EHA Library, Dillon RICHARD, 386332

UPDATED DATA FOR ZIFTOMENIB IN PATIENTS WITH NPM1-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

EHA Library, Amir Fathi, 386333

THE PROGNOSTIC SIGNIFICANCE OF THE MEASURABLE RESIDUAL DISEASE STATUS WITHIN THE THREE AML ELN2022 RISK GROUPS

EHA Library, Lara Bischof, 386337

PREDICTORS OF RESPONSE AND OUTCOME IN PATIENTS WITH REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA RECEIVING VENETOCLAX WITH NON-INTENSIVE CHEMOTHERAPY

EHA Library, Katja Krüger, 386339

A PHASE 1B/2 STUDY OF TP-0903 AND DECITABINE TARGETING MUTANT TP53 AND/OR COMPLEX KARYOTYPE IN PATIENTS WITH UNTREATED ACUTE MYELOID LEUKEMIA (AML) ≥ AGE 60 YEARS: FINAL RESULTS

EHA Library, Alice Mims, 386341

MOLECULAR PATTERN BY AGE AND OVERALL SURVIVAL IN ACUTE MYELOID LEUKEMIA: A POPULATION-BASED STUDY FROM THE SWEDISH AML REGISTRY.

EHA Library, Gunnar JULIUSSON, 386342

RISK STRATIFICATION BY NOMOGRAM SCORING SYSTEM OF NPM1-MUTATED CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIALEUKAEMIA BASED ON A MULTI-GENE PANEL

EHA Library, Mingyue Zhao, 386348

OFF-THE-SHELF CD33 CAR-NK CELL THERAPY FOR RELAPSE/REFRACTORY AML: FIRST-IN-HUMAN, PHASE I TRIAL

EHA Library, Ruihao Huang, 386351

DISTINCTIVE CLONAL EVOLUTION PATTERN AND PROGNOSTIC SIGNIFICANCE OF THE CLONALITY OF KRAS MUTATIONS IN KMT2A-REARRANGED ACUTE MYELOID LEUKEMIA

EHA Library, Hidemasa Matsuo, 386356

CAN MULTIPARAMETRIC FLOW CYTOMETRY OF PERIPHERAL BLOOD CHALLENGE BONE MARROW ANALYSES FOR DETECTION OF MEASURABLE RESIDUAL DISEASE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA?

EHA Library, Jonas Schadt, 386357

THE EFFECT OF AGE AND TREATMENT ON THE PREDICTIVE VALUE OF MEASURABLE RESIDUAL DISEASE: IMPLICATIONS FOR THE CLINICAL MANAGEMENT OF ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA

EHA Library, Francesco Mannelli, 386358

CPX-351 INDUCTION IS ABLE TO INDUCE MRD NEGATIVE CR IN A SIGNIFICATIVE PROPORTION OF VERY HIGH RISK AML PATIENTS, REGARDLESS OF MUTATIONAL BURDEN, ALLOWING FOR BRIDGING TO TRANSPLANTATION

EHA Library, Carola Riva, 386359

A FULLY AUTOMATED SUPERVISED AI-BASED CELL CLASSIFIER TO ACCURATELY FLAG PATHOLOGICAL SIGNATURE CELLS IN 28,285 REAL-WORLD BLOOD SMEARS

EHA Library, Christopher Maier, 386362

EFFICACY OF INTRAVENOUS IRON TREATMENT FOR CANCER PATIENT WITH ANEMIA, RANDOMIZED CONTROLLED STUDY

EHA Library, Jun Ho Jang, 388011

IS BREXUCABTAGENE AUTOLEUCEL A COST-EFFECTIVE TREATMENT FOR REFRACTORY/RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA? A PHARMACOECONOMIC ANALYSIS IN THE PERSPECTIVE OF THE PUBLIC HEALTHCARE SYSTEM.

EHA Library, Monia Marchetti, 388012

MYELODYSPLASIA-RELATED MUTATIONS IN THE NEW ELN CLASSIFICATION: DOES CLONAL SIZE PLAY A ROLE?

EHA Library, Christian Rausch, 386263

NOVEL COMPOUNDS TO TARGET KMT2A-REARRANGED PEDIATRIC ACUTE MYELOID LEUKEMIA

EHA Library, Claudia Tregnago, 386264

INTRACELLULAR CITRATE LEVELS MODULATE ANTI-APOPTOTIC PROTEINS TO ENHANCE VENETOCLAX SENSITIVITY IN ACUTE MYELOID LEUKEMIA STEM CELLS

EHA Library, Aykut Demir, 386267

RNA SEQUESTRATION IN P-BODIES PROMOTES LEUKEMIA ONSET AND PROGRESSION

EHA Library, Ludovica Proietti, 386268

ENHANCER HIJACKING IN COMPLEX-KARYOTYPE AML

EHA Library, Etienne Sollier, 386269

DDX41 GERMLINE VARIANTS: POPULATION PREVALENCE, SIGNIFICANCE AND LEUKEMIC EVOLUTION

EHA Library, Sruthi Cheloor Kovilakam, 386271

SINGLE CELL RNASEQ UNCOVERING THE ROLE OF A LEUKEMIC DRIVER GENE FUSION CBFΒ::MYH11 IN THE LEUKEMIC–NICHE SIGNALING

EHA Library, Polina Derevyanko, 386273

A SYSTEMS-BASED APPROACH TO UNVEIL DRUG RESISTANCE IN FLT3-ITD AML

EHA Library, Francesca Sacco, 386274

COMPREHENSIVE CHARACTERIZATION OF DIFFERENTIAL GENE EXPRESSION AND ISOFORM USAGE IN SPLICING FACTOR-MUTATED ACUTE MYELOID LEUKEMIA USING LONG-READ SEQUENCING

EHA Library, Klaus Metzeler, 386275

DECIPHERING THE MITOPHAGY RECEPTOR NETWORK IDENTIFIES A CRUCIAL ROLE FOR OPTINEURIN IN ACUTE MYELOID LEUKEMIA

EHA Library, Sebastian Koschade, 386276

PROTEOGENOMIC PROFILING OF DIAGNOSTIC AND RELAPSE SAMPLES IN PEDIATRIC ACUTE MYELOID LEUKEMIA

EHA Library, Tina Glisovic-Aplenc, 386278

ALDH1A AS A THERAPEUTIC TARGET IN ACUTE MYELOID LEUKEMIA

EHA Library, Mehak Shaikh, 386279

NOVEL INSIGHTS INTO MINIMAL RESIDUAL DISEASE OF ACUTE MYELOID LEUKEMIA USING PRIMARY SAMPLES AND A CLINICALLY RELEVANT PDX MODEL.

EHA Library, Nesrine Aroua, 386282

ACUTE MYELOID LEUKEMIA (AML) WITH IDH1 AND IDH2 MUTATIONS CAN BE EFFECTIVELY RISK STRATIFIED BASED ON THE PRESENCE ADVERSE RISK GENOMIC FEATURES.

EHA Library, Nikhil Patkar, 386283

DISEASE MONITORING OF NPM1-MUTANT (MUT) ACUTE MYELOID LEUKEMIA (AML) USING MEASURABLE RESIDUAL DISEASE (MRD) ASSESSMENTS DURING ORAL AZACITIDINE (ORAL-AZA) TREATMENT (TX): A QUAZAR AML-001 SUBANALYSIS

EHA Library, Gail Roboz, 386288

ERK1/2 INHIBITION OVERCOMES RESSITANCE TO BCL2 INHIBITION IN ACUTE MYELOID LEUKEMIA BY IMPACT ON MITOCHONDRIAL DYNAMICS AND FUNCTION

EHA Library, Gautam Borthakur, 386289

THE FLT3 RECEPTOR IS INVOLVED IN THE ENDOPLASMIC RETICULUM HOMEOSTASIS AND GLUCOSE METABOLISM STATUS IN ACUTE MYELOID LEUKEMIA

EHA Library, Maria Turos Cabal, 386290

RECIPIENT SEX AND DONOR RISK GROUP INFLUENCE LEUKEMIA KINETICS IN NSG MICE

EHA Library, Marlon Arnone, 386291

N-MYRISTOYLATION INHIBITION ABROGATES OXIDATIVE PHOSPHORYLATION TO TARGET ACUTE MYELOID LEUKEMIA STEM CELLS

EHA Library, Erwan Beauchamp, 386294

LONG NON-CODING RNA SNHG29 IS A NOVEL MYELOID LEUKEMIA DEPENDENCY

EHA Library, Robert Winkler, 386296

ACUTE MYELOID LEUKEMIA DRIVES BCL-2 UPREGULATION IN NON MALIGNANT HSPCS WHICH IS TARGETED BY VENETOCLAX AND CAUSES CYTOPENIA

EHA Library, Dominic Fowler-Shorten, 386298

POLO-LIKE KINASE 4 INHIBITION INDUCED ANTI-LEUKAEMIC EFFECTS THROUGH HISTONE MODIFICATION IN TP53 MUTATED ACUTE MYELOID LEUKAEMIA

EHA Library, Wing Lam, 386300

EMERGING LEUKEMIA ASSOCIATED IMMUNOPHENOTYPES (LAIPS) IN BONE MARROW OF ACUTE MYELOID LEUKEMIA PATIENTS AFTER INTENSIVE CHEMOTHERAPY.

EHA Library, Lok Lam Ngai, 386304

AN ORAL COMBINATION THERAPY OF OR-2100 AND VENETOCLAX IN ACUTE MYELOID LEUKEMIA

EHA Library, Kazuharu Kamachi, 386305

COMBINATION OF DIFFERENT IMMUNOTHERAPEUTIC DRUGS ENHANCES SPECIFIC T CELL IMMUNE RESPONSES AGAINST LEUKEMIC CELLS AND LEUKEMIC PROGENITOR/STEM CELLS IN ACUTE MYELOID LEUKEMIA

EHA Library, Jochen Greiner, 386306

MOLECULAR CHARACTERIZATION OF EXTRAMEDULLARY LOCALIZATIONS IN ACUTE MYELOID LEUKEMIA (AML)

EHA Library, Giorgia Silvestrini, 386307

TREATMENT IS SHAPING CLONAL EVOLUTION AND RESISTANCE PATTERNS IN MURINE KMT2A-REARRANGED LEUKEMIA WITH SUBCLONAL FLT3N676K

EHA Library, Ton Falqués Costa, 386308

DNMT AND HDAC INHIBITION INDUCES IMMUNOGENIC NEOANTIGENS FROM HUMAN ENDOGENOUS RETROVIRAL ELEMENT-DERIVED TRANSCRIPTS

EHA Library, ASHISH GOYAL, 386309

QUANTUM-FIRST TRIAL: FLT3-ITD–SPECIFIC MEASURABLE RESIDUAL DISEASE (MRD) CLEARANCE IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL

EHA Library, Mark Levis, 386312

GEMTUZUMAB-BASED INDUCTION CHEMOTHERAPY COMBINED WITH MIDOSTAURIN FOR FLT3 MUTATED AML. UPDATED TOXICITY AND INTERIM SURVIVAL ANALYSIS FROM THE NCRI AML19V2 “MIDOTARG” PILOT TRIAL

EHA Library, Nigel Russell, 386313

REAL-WORLD EFFECTIVENESS AND SAFETY OF CPX-351 IN PATIENTS AGED <60 AND ≥60 YEARS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: CREST-UK POST-HOC ANALYSIS

EHA Library, Priyanka Mehta, 386315

MIDOSTAURIN PLASMA EXPOSURE IN PATIENTS WITH FLT3-MUT ACUTE MYELOID LEUKEMIA UNDERGOING POSACONAZOLE PROPHYLAXIS DURING INDUCTION TREATMENT: A PROSPECTIVE MULTICENTRE STUDY FROM THE SEIFEM GROUP

EHA Library, Francesco MARCHESI, 386316

PROGNOSTIC IMPACT OF “MULTI-HIT” VERSUS “SINGLE-HIT” TP53 MUTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: RESULTS FROM THE CONSORTIUM ON MYELOID MALIGNANCIES AND NEOPLASTIC DISEASES (COMMAND)

EHA Library, Talha Badar, 386318

DAY 14 MEASURABLE RESIDUAL DISEASE ASSESSMENT PREDICTS TREATMENT OUTCOMES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH INTENSIVE CHEMOTHERAPY - RESULTS OF THE PALG-AML1/2016 STUDY

EHA Library, Agnieszka Wierzbowska, 386320

UNLOCKING THE POTENTIAL OF SYNTHETIC PATIENTS FOR ACCELERATING CLINICAL TRIALS: RESULTS OF THE FIRST GIMEMA EXPERIENCE

EHA Library, Alfonso Piciocchi, 386324

PHENOTYPIC SUBTYPES OF LEUKEMIC TRANSFORMATION IN CHRONIC MYELOMONOCYTIC LEUKEMIA

EHA Library, Guillermo Montalban-Bravo, 386325

INCIDENCE, RISK FACTORS AND OUTCOMES OF SECOND NEOPLASMS IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA: THE PETHEMA-PALG EXPERIENCE.

EHA Library, Marta Sobas, 386327

APPLICABILITY OF 2022 CLASSIFICATIONS OF ACUTE MYELOID LEUKEMIA IN THE REAL-WORLD SETTING

EHA Library, Enrico Attardi, 386328

SUPERIOR OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION AMONG PATIENTS ≥ 60 YEARS TREATED WITH CLADRIBINE, LOW DOSE CYTARABINE PLUS VENETOCLAX FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA

EHA Library, Jayastu Senapati, 386329

PHASE II STUDY ON VENETOCLAX PLUS DECITABINE FOR ELDERLY (≥60 <75YEARS) PATIENTS WITH NEWLY DIAGNOSED HIGH-INTERMEDIATE RISK AML ELEGIBLE FOR ALLO-SCT : MIDTERM UPDATE OF VEN-DEC GITMO STUDY

EHA Library, Domenico Russo, 386331

GIMEMA AML1819 TRIAL: GEMTUZUMAB OZOGAMICIN PLUS INTENSIVE CHEMOTHERAPY IMPACTS ON THE LEVEL OF POST-CONSOLIDATION MEASURABLE RESIDUAL DISEASE (MRD) IN ACUTE MYELOID LEUKEMIA

EHA Library, Adriano Venditti, 386334

CLINICAL VALIDATION OF THE NORDIC GUIDELINES FOR GERMLINE TESTING IN MYELOID NEOPLASMS: RESULTS FROM A MULTI-CENTER PROSPECTIVE COHORT STUDY

EHA Library, Panagiotis Baliakas, 386335

SALVAGE THERAPY WITH VENETOCLAX IN COMBINATION WITH AZACITIDINE, HOMOHARRINGTONINE AND CYTARABINE IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA

EHA Library, Zhao Xingli, 386336

THE IMPACT OF THE NUMBER OF RAS MUTATIONS IN THE OUTCOMES OF PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED FRONTLINE AT A SINGLE INSTITUTION.

EHA Library, Mahesh Swaminathan, 386338

INTEGRATION OF TRANSCRIPTOMIC FEATURES IMPROVES PROGNOSIS PREDICTION OF PEDIATRIC ACUTE MYELOID LEUKEMIA WITH KMT2A REARRANGEMENTS

EHA Library, Jun Li, 386340

TREATMENT PATTERNS AND REAL-WORLD OUTCOMES OF MOLECULAR SUBGROUPS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA RECEIVING FRONTLINE VENETOCLAX-BASED THERAPY

EHA Library, Curtis Lachowiez, 386343

VENETOCLAX AND AZACITIDINE COMBINED WITH CHIDAMIDE (VAC) FOR THE TREATMENT OF NEWLY DIAGNOSED ACUTE MONOCYTIC LEUKEMIA PATIENTS

EHA Library, Shengli Xue, 386347

POINT OF CARE CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH ABERRANT CD19 ANTIGEN EXPRESSION

EHA Library, Ivetta Danylesko, 386349

FINDINGS FROM AN ANALYSIS OF PATIENTS WITH MONOCYTIC AND MONOCYTIC-LIKE ACUTE MYELOID LEUKEMIA (AML), INCLUDING AML-M4 AND AML-M5, TREATED WITH VENETOCLAX (VEN) PLUS AZACITIDINE (AZA)

EHA Library, Marina Konopleva, 386350

THE COMPARISON OF VFLAI, FLAI AND 3+7 REGIMENS BY MULTILEVEL PROPENSITY SCORE WEIGHTING HIGHLIGHTS THE BENEFIT OF THE ADDITION OF VENETOCLAX IN NO LOW-RISK AML TREATED IN GIMEMA TRIALS AND REAL WORLD

EHA Library, Alfonso Piciocchi, 386352

PHARMACODYNAMICALLY DEFINED METRONOMIC DOSING OF DECITABINE AND VENETOCLAX IN ACUTE MYELOID LEUKEMIA

EHA Library, Mendel Goldfinger, 386353

LONG-TERM OUTCOMES OF STEM CELL TRANSPLANT IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH VENETOCLAX + HMA THERAPIES

EHA Library, Keith Pratz, 386354

SAFETY AND EFFICACY UPDATE FROM CLI120-001: A PHASE1B DOSE ESCALATION STUDY IN RELAPSE-REFRACTORY ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASIA

EHA Library, Ewa Lech-Marańda, 386355

MIDOSTAURIN PLUS 7+3 OR QUIZARTINIB PLUS 7+3 IN FLT3-ITD MUTATED AML

EHA Library, Adolfo De La Fuente, 386360

KINETICS AND PROGNOSTIC VALUE OF MEASURABLE RESIDUAL DISEASE (MRD) IN PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH VENETOCLAX IN COMBINATION WITH HYPOMETHYLATING AGENTS.

EHA Library, Carlos Jimenez-Vicente, 386361

VENETOCLAX PLUS AZACITIDINE DELAYS DETERIORATION OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: VIALE-A LONG-TERM FOLLOW UP

EHA Library, Keith Pratz, 388010

HEALTH ECONOMIC EVALUATION OF THIRD-LINE INTERVENTIONS FOR TRANSPLANT-INELIGIBLE RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN GERMANY

EHA Library, Melina Sophie Kurte, 388013